Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Double-Blind Randomized Study of V116 vs PPSV23 in At-Risk Children and Adolescents
jRCT2031230559Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2024
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of pneumococcal 21-valent conjugate vaccine in pneumococcal disease (2 arms), sponsored by Merck & Co. Primary endpoints: Serotype-specific OPA responses at 30 days postvaccination, Solicited adverse events and 1 more. Started Feb 2024; status: completed.
02
Drugs
pneumococcal 21-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on jRCT2031230559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230559.